follow recent earn report publish updat model forecast
buy pt
updat model account beat well incorpor
pend acquisit ge biopharma start adjust
ep reflect impact ge-rel equiti financ
partial off-set flow-through beat revis ep
reflect anticip accret ge deal high-end
accret target assum core growth ge
line expect growth trajectori next year
think could somewhat conserv especi light acceler momentum
busi
yesterday ge report robust result biopharma segment order
acceler vs revenu grew
overal strength consist seen player across
bioprocess landscap sartoriu bp segment rev order
biopharma dd core also underscor view deal assumpt
ge asset like beatabl
also rais pt impli ep
premium peer group justifi structur improv growth profil
defens recur mix scope potenti upsid ge deal synergi
thermo fisher scientif hold pt
updat model account beat/rais well impact
brammer acquisit close today month earlier
expect guidanc assum close brammer ad
ep figur slightli earlier close like add anoth
togeth rais ep ep move
modest tweak omx interest expens assumpt
well sharper account ap divestitur dilut dcf-base
pt move impli ev/ebitda slight premium peer
ep
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
pleas see import disclosur inform page report
pleas see import disclosur inform page report
danah corporationhistor project statement incomedollar million except per share amount fiscal year end decemb histor net product incom incom share share analysisgross research sg ebitda oper margin incom net omx y/i analysisnet gross research sg oper incom net dilut danah corpor jefferi llc equiti research
pleas see import disclosur inform page report
thermo fisher scientif inc histor project statement incomedollar million except per share amountshistor net product incom expens share share analysisgross sg oper margin incom incom net growth analysisnet sg oper incom net dilut thermo fisher scientif jefferi llc equiti research
estim valuat
pleas see import disclosur inform page report
profil attract merit howev see less room
rel absolut multipl expans believ valuat
alreadi discount tmo safe-haven statu out-year ep
lt earn compound-annual-growth-rate incl
organ revenu growth
nopat compound-annual-growth-rate next decad
pthn total ebita synergi
price target impli price-to-earnings ep ev
pthn faster synergi captur
bolt-on thru
price target base price-to-earnings ep ev
organ revenu growth formal
disrupt sales/suppli chain due tariff
price target impli price-to-earnings ep
pleas see import disclosur inform page report
estim valuat
pleas see import disclosur inform page report
